Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Benjamin Wolfson"'
Autor:
S. Elizabeth Franks, Kellsye P. Fabian, Ginette Santiago-Sánchez, Benjamin Wolfson, James W. Hodge
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Immune checkpoint blockade (ICB) therapy, while groundbreaking, must be improved to promote enhanced durable responses and to prevent the development of treatment-refractory disease. Cancer therapies that engage, enable, and expand the antitumor immu
Externí odkaz:
https://doaj.org/article/d1c205af3126416db25719406b38af02
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Cancer treatment has rapidly entered the age of immunotherapy, and it is becoming clear that the effective therapy of established tumors necessitates rational multi-combination immunotherapy strategies. But even in the advent of immunotherapy, the cl
Externí odkaz:
https://doaj.org/article/14decf0c136548b9b4620fcde3f44a8e
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Background There are highly effective treatment strategies for estrogen receptor (ER)+, progesterone receptor (PR)+, and HER2+ breast cancers; however, there are limited targeted therapeutic strategies for the 10%–15% of women who are diagnosed wit
Externí odkaz:
https://doaj.org/article/7f0a8e2593fb407eb6c3fc1bb6d0702d
Autor:
Benjamin Wolfson, James W. Hodge
Publikováno v:
ImmunoMedicine, Vol 1, Iss 1, Pp n/a-n/a (2021)
Abstract The development and FDA approval of immune checkpoint blocking antibodies have brought new light to cancer immunotherapy. While immune checkpoint blockade (ICB) has demonstrated clinical benefit in certain tumors as monotherapy, effective th
Externí odkaz:
https://doaj.org/article/74dc3647782c47e999da629b025c6de6
Autor:
Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, James W. Hodge
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-14 (2018)
Abstract Background Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining
Externí odkaz:
https://doaj.org/article/4f6eac2c2b1c4a31bc564e9a3f29ade8
Publikováno v:
Vaccines, Vol 9, Iss 5, p 509 (2021)
Effective treatment of established tumors requires rational multicombination immunotherapy strategies designed to target all functions of the patient immune system and tumor immune microenvironment. While these combinations build on the foundation of
Externí odkaz:
https://doaj.org/article/f963ddcad4bc425a96cb302b41bb9089
Publikováno v:
Cancers, Vol 12, Iss 8, p 2131 (2020)
Cellular therapy has emerged as an attractive option for the treatment of cancer, and adoptive transfer of chimeric antigen receptor (CAR) expressing T cells has gained FDA approval in hematologic malignancy. However, limited efficacy was observed us
Externí odkaz:
https://doaj.org/article/00c3694699da4684be4bca45668c0dcf
Autor:
Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong, James W. Hodge
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-2 (2019)
Following publication of the original article [1], an error was noted in the GAPDH in the western blot depicted in Figure 4b.
Externí odkaz:
https://doaj.org/article/2aaa4f9c0dd249a4b7a5b8f2dfa0bef1
Autor:
James W. Hodge, Jeffrey Schlom, Houssein Abdul Sater, Rika Fujii, Benjamin Wolfson, Kristen Solocinski, Michelle R. Padget, Anthony S. Malamas, Kellsye P. Fabian
Supplemental figures s1-s3 and supplementary table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8283f054f681cf562a94a185e717e50
https://doi.org/10.1158/2326-6066.22543390
https://doi.org/10.1158/2326-6066.22543390
Autor:
James W. Hodge, Jeffrey Schlom, Houssein Abdul Sater, Rika Fujii, Benjamin Wolfson, Kristen Solocinski, Michelle R. Padget, Anthony S. Malamas, Kellsye P. Fabian
Immunotherapy of immunologically cold solid tumors may require multiple agents to engage immune effector cells, expand effector populations and activities, and enable immune responses in the tumor microenvironment (TME). To target these distinct phen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4f8c7c67f98dcbaf90b406c99ca1760
https://doi.org/10.1158/2326-6066.c.6550240
https://doi.org/10.1158/2326-6066.c.6550240